Skip to main content
Clinical Trials/NCT07625137
NCT07625137Not yet recruitingNot Applicable

Expanding Opportunistic Bilateral Salpingectomy to Laparoscopic Cholecystectomy to Prevent Ovarian Cancer: A Feasibility and Safety Trial

University of British Columbia3 sites in 1 country240 target enrollmentStarted: July 1, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
240
Locations
3

Study Overview

Brief Summary

This study aims to evaluate the feasibility, safety, and cost-effectiveness of opportunistic salpingectomy (OS-the removal of the fallopian tubes) at the time of laparoscopic cholecystectomy (the removal of the gallbladder) to prevent ovarian cancer. Ovarian cancer is the fifth leading cause of cancer-related mortality in females in Canada. OS can prevent the most common and lethal type of ovarian cancer, high-grade serous carcinoma (HGSC). OS during gynecologic surgery (hysterectomy or instead of tubal ligation) is safe and effective. However, rates of hysterectomies and tubal sterilization are decreasing. This research team aims to extend the prevention of ovarian cancer by expanding to offer OS during other surgeries in the abdomen, when patients are already undergoing a surgical procedure. This study will examine: 1) the feasibility of OS at the time of laparoscopic cholecystectomy; 2) the safety of OS at the time of laparoscopic cholecystectomy; 3) any health services consequences of offering OBS during laparoscopic cholecystectomy.

The hypothesis is that OS at the time of laparoscopic cholecystectomy is a feasible, safe, and cost-effective primary prevention strategy for ovarian cancer. It is also hypothesized that there will be 10-20 minutes of additional operating room time for completing OS, and that integrating the identified partners and knowledge users, as well as adding relevant knowledge users as the project progresses, will affect the rapid mobilization of our findings.

Detailed Description

The investigators will conduct a multi-center, open-label, non-inferiority clinical trial with two sites in British Columbia, Canada, and one site in Ontario, Canada. Recruitment will take place over 30 months from July 1, 2026, to January 31, 2029. Participants will be followed from preoperative assessment until 30 days following discharge from their surgery. The investigators will choose the nearest neighbor match by age at the same site as the intervention patient. The research coordinators (RC) will run each potential eligible control patient by the surgeon running that site to ensure that they would have been eligible for the trial, and their data will be obtained from their electronic medical record. All identifiable data will be removed and replaced with study IDs.

The RC at each site will have access to the electronic booking system at their site and screen eligible patients. They will approach patients and offer them the option to participate in a trial of opportunistic bilateral salpingectomy (OBS) during their laparoscopic cholecystectomy. If patients are interested, they will be provided with an information leaflet which includes a link to an online video, developed for patients, explaining OBS during general surgery. They will be provided with the electronic consent documents by email and offered a paper version should they prefer that option. Should there be any instances where an in-person consenting may not be possible or inconvenient, it will be done over the phone.

The investigators anticipate that 240 OBS patients will be recruited at the end of 30 months, which will ensure sufficient power for the main safety aims. The RC will attend the OR and will collect data on the fallopian tube removal. In the rare instances where the RC is not present, an OR nurse or another person in the OR will perform those duties. The RC will record how long it takes for the surgeon to remove both fallopian tubes. If the patient has had a prior tubal ligation, the surgeon will report that to the RC.

Start time: RC will begin timing fallopian tube removal when the camera and instruments are positioned away from the abdomen and into the pelvis, with or without insertion of additional port sites. The surgeon will signal when fallopian tube removal begins.

End time: The fallopian tube removal will be considered finished when both tubes are separated from the ovaries and uterus. The surgeon will signal when both tubes are separated from the ovaries and uterus, or when the attempt to remove both fallopian tubes was abandoned in cases where OBS was not feasible.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
35 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Individuals with fallopian tubes who are undergoing lap chole and have more than 24 hours from surgeon consult to surgery, regardless of menopausal status
  • Age of 35 years and older
  • Patient must be able to give oral and written informed consent
  • Premenopausal patients will be included but will be counseled regarding their fertility

Exclusion Criteria

  • Less than 24 hours available from surgeon consult to surgery
  • Individuals with a desire for a future pregnancy
  • Previously had a salpingectomy or salpingo-oophorectomy

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Gillian Hanley

Associate Professor

University of British Columbia

Study Sites (3)

Loading locations...

Similar Trials